Funded Projects
Explore our currently funded projects. You may search with all three fields, then focus your results by applying any of the dropdown filters. After customizing your search, you may download results and even save your specific search for later.
Project # | Project Title | Research Focus Area | Research Program | Administering IC | Institution(s) | Investigator(s) | Location(s) | Year Awarded |
---|---|---|---|---|---|---|---|---|
1R01DA059471-01
Show Summary |
Medications for Opioid Use Disorder Differentially Modulate Intrinsically Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment | New Strategies to Prevent and Treat Opioid Addiction | Sleep Dysfunction as a Core Feature of Opioid Use Disorder and Recovery | NIDA | UNIVERSITY OF ALABAMA AT BIRMINGHAM | CROPSEY, KAREN L (contact); GAMBLE, KAREN L | Birmingham, AL | 2023 |
NOFO Title: HEAL Initiative: Sleep Predictors of Opioid-Use Disorder Treatment Outcomes Program (R01 Clinical Trial Optional)
NOFO Number: RFA-DA-23-059 Summary: People who use opioids, as well as those who take medications approved by the U.S. Food and Drug Administration for opioid use disorder (OUD), report significant problems with sleep and biological rhythms. This project will explore the activity of a novel group of photosensitive neurons in the retinas, a potential source for sleep disturbances in these individuals. The research could lead to new treatment strategies and responses, but also may identify a non-invasive, circadian biomarker to predict recovery and relapse in people with OUD. |
||||||||
1RM1DA059375-01
Show Summary |
HEAL Initiative: Research to Foster an Opioid Use Disorder Treatment System Patients Can Count On | Translation of Research to Practice for the Treatment of Opioid Addiction | Optimizing the Quality, Reach, and Impact of Addiction Services | NIDA | RESEARCH TRIANGLE INSTITUTE | MARK, TAMI L | Research Triangle Park, NC | 2023 |
NOFO Title: HEAL Initiative: Research to Foster an Opioid Use Disorder Treatment System Patients Can Count On (RM1 - Clinical Trial Optional)
NOFO Number: RFA-DA-23-046 Summary: Although medication-based treatment for opioid use disorder can effectively reduce overdose risk and improve health outcomes, most people discontinue treatment too soon. Quality measures that inform opioid treatment programs about how many patients remain in treatment relative to peer programs could motivate those programs to pursue quality improvement activities, such as helping patients navigate logistical barriers to receiving treatment. This project will test approaches to developing and disseminating retention and outcome measures for opioid treatment programs. |
||||||||
1R61DA059880-01
Show Summary |
Evaluation of a Peer Recovery Support Program Adapted to Target Retention in Clinic-Based Medication for Opioid Use Disorder Treatment | Translation of Research to Practice for the Treatment of Opioid Addiction | Optimizing the Quality, Reach, and Impact of Addiction Services | NIDA | GEISINGER CLINIC | POULSEN, MELISSA (contact); ZAJAC, KRISTYN | Danville, PA | 2023 |
NOFO Title: HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional)
NOFO Number: RFA-DA-23-053 Summary: Medications for opioid use disorder (OUD) are safe and effective. However, many people do not take them long enough to achieve sustained recovery, putting them at risk of overdose. Peer recovery support services—which are delivered by trained individuals with lived experience of addiction and recovery—may help people with OUD initiate and stay in medication treatment. This project will adapt peer recovery support services for use in outpatient substance use treatment settings and test their implementation and effectiveness in helping people with OUD achieve long-term recovery. If successful, the program could be implemented in a variety of outpatient treatment programs, including in underserved rural areas. |
||||||||
1UG3DA059407-01
Show Summary |
Towards Treatment for the Complex Patient: Investigations of Low-Intensity Focused Ultrasound | New Strategies to Prevent and Treat Opioid Addiction | Optimizing Care for People with Opioid Use Disorder and Mental Health Conditions | NIDA | INSTITUTE FOR CLINICAL RESEARCH, INC. | LEE, MARY (contact); LEGON, WYNN | Washington, D.C | 2023 |
NOFO Title: HEAL Initiative: Therapeutics Development for Opioid Use Disorder in Patients with Co-occurring Mental Disorders (UG3/UH3 - Clinical Trial Optional)
NOFO Number: RFA-DA-23-049 Summary: Patients with opioid use disorder and co-occurring chronic pain and anxiety are at the highest risk for opioid overdose deaths. Low-intensity focused ultrasound (LIFU) is an innovative, noninvasive method that can be used to alter brain activity and potentially repair dysfunctional brain circuits involved in these disorders. This project will examine how LIFU directed to a small but critical brain region implicated in all three of these disorders, the anterior insula, can reduce drug craving, pain response, and anxiety symptoms as well as improve the physiological processes that may underlie the symptoms experienced by these patients. |
||||||||
1RF1NS131812-01A1
Show Summary |
Targeting Checkpoint Inhibitors for Pain Control | Preclinical and Translational Research in Pain Management | Discovery and Validation of Novel Targets for Safe and Effective Treatment of Pain | NINDS | DUKE UNIVERSITY | JI, RU-RONG | Durham, NC | 2023 |
NOFO Title: HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)
NOFO Number: RFA-NS-22-034 Summary: Immune checkpoint proteins regulate the immune system to prevent it from indiscriminately attacking cells. Some cancers activate these immune checkpoints to avoid attack, and drugs that target certain immune checkpoints are approved for cancer treatment. The same pathway may also be involved in pain because immune checkpoint proteins, such as programmed death 1 (PD-1) and the molecule that binds to it (programmed death ligand 1 [PD-L1]), also are found in sensory neurons, microglia, and macrophages. This project will investigate PD-1/PD-L1 in different cell populations to determine their contribution to pain and to the effects of opioids such as morphine. This knowledge may help identify new drugs for pain management that modify immune checkpoint activity. |
||||||||
1K99AR083482-01
Show Summary |
Elucidating the Neuroimmune Mechanisms Underlying Pain and Inflammation in Autoimmune Arthritis | Cross-Cutting Research | Training the Next Generation of Researchers in HEAL | NIAMS | BOSTON CHILDREN'S HOSPITAL | JAIN, AAKANKSHA | Boston, MA | 2023 |
NOFO Title: HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research (K99/R00 Independent Clinical Trial Not Allowed)
NOFO Number: RFA-NS-22-022 Summary: Rheumatoid arthritis is an autoimmune disease characterized by episodes of joint inflammation and pain. There are currently no safe and effective treatments that achieve long-term remission of the condition or the associated pain. Many patients use opioid medications to manage the pain and are at increased risk of developing opioid use disorder; therefore, additional treatment options are needed. In rheumatoid arthritis, pain-triggering sensory neurons interact with immune cells in the joints. This project aims to dissect the neuroimmune crosstalk underlying pain and inflammation in arthritic joints and uncover novel therapeutic avenues for this painful condition. |
||||||||
1UG3NS135173-01
Show Summary |
Developing Radiocaine NaV imaging as a response monitoring biomarker for chronic pain | Clinical Research in Pain Management | Discovery and Validation of Biomarkers, Endpoints, and Signatures for Pain Conditions | NINDS | LUTROO IMAGING LLC | NORWOOD, BRAXTON (contact); IBRAHIM, MOHAB M | Kalispell, MT | 2023 |
NOFO Title: HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3 Clinical Trial Optional)
NOFO Number: RFA-NS-22-050 Summary: There are currently no reliable tools to measure pain objectively, and health care providers must rely on patient’s subjective reports and observations of patient behavior to determine the level of pain a person experiences. This hampers both effective pain management and the development of new pain medications. This project will assess an imaging technology called Radiocaine that in animal studies has been able to identify the origin of pain as well as its intensity. The goal is to use Radiocaine in clinical trials for pain treatments, thereby enhancing treatment effectiveness and facilitating development of new treatments. |
||||||||
1R42NS132622-01
Show Summary |
Targeting TLR4-lipid rafts to prevent postoperative pain | Cross-Cutting Research | Small Business Programs | NINDS | RAFT PHARMACEUTICALS, LLC | DOUGHERTY, PATRICK M (contact); KOGAN, YAKOV | San Diego, CA | 2023 |
NOFO Title: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)
NOFO Number: RFA-NS-20-009 |
||||||||
1R01DA059371-01
Show Summary |
The Impact of Community Infrastructure Reinvestment Programs on Opioid Misuse and Opioid Overdose | New Strategies to Prevent and Treat Opioid Addiction | Preventing Opioid Use Disorder | NIDA | UNIVERSITY OF PENNSYLVANIA | NESOFF, ELIZABETH | Philadelphia, PA | 2023 |
NOFO Title: HEAL Initiative: Preventing Opioid Misuse and Co-Occurring Conditions by Intervening on Social Determinants (R01 - Clinical Trials Optional)
NOFO Number: RFA-DA-23-051 Summary: Urban neighborhood deterioration (also known as blight) can affect individual and community health. Interventions have shown positive effects on neighborhood crime, gun violence, and mental health. In Philadelphia, government and community partnerships have remediated vacant lots and abandoned buildings to improve living conditions. This project will investigate the degree to which neighborhood improvement interventions in Philadelphia affect opioid misuse and overdose risk for residents. Results from this research could inform similar public health-based policy and community-level health interventions in other cities. |
||||||||
1U01DA059472-01
Show Summary |
Value of Sleep Metrics in Predicting Opioid Use Disorder Treatment Outcomes: Leadership and Data Coordinating Center | New Strategies to Prevent and Treat Opioid Addiction | Sleep Dysfunction as a Core Feature of Opioid Use Disorder and Recovery | NIDA | HARVARD PILGRIM HEALTH CARE, INC. | WANG, RUI (contact); PURCELL, SHAUN M; REDLINE, SUSAN S | Canton, MA | 2023 |
NOFO Title: HEAL Initiative - Sleep Predictors of Opioid-Use Disorder Treatment Outcomes Program: Leadership and Data Co-ordinating Center (U01 Clinical Trial Optional)
NOFO Number: RFA-DA-23-060 Summary: Chronic opioid use has well-known effects on sleep quality and circadian rhythms, but few predictive metrics core to mental and physical health and well-being are available to guide treatment with medications for opioid use disorder (OUD). This project will identify observable characteristics related to sleep and circadian rhythms that predict OUD treatment outcomes, toward refining treatment strategies and developing new ones. This data coordinating center will ensure that (1) high quality and standardized data are collected across all research sites, (2) all milestones and regulatory requirements are met, (3) study results are reported in a timely manner, and (4) that data and results are disseminated broadly. |
||||||||
1R61DA059033-01A1
Show Summary |
Implementing a Patient Navigation Intervention Across a Health System to Address Treatment Entry Inequities | Translation of Research to Practice for the Treatment of Opioid Addiction | Optimizing the Quality, Reach, and Impact of Addiction Services | NIDA | FRIENDS RESEARCH INSTITUTE, INC. | ALEXANDER, KAREN (contact); GRYCZYNSKI, JAN | Baltimore, MD | 2023 |
NOFO Title: HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional)
NOFO Number: RFA-DA-23-053 Summary: Significant racial, ethnic, socioeconomic, and geographic disparities affect access to opioid use disorder (OUD) treatment and have thus contributed to the opioid overdose crisis. Patient navigator interventions after hospitalization can improve access to treatment, but challenges prevent full adoption of these strategies. These include lack of coordination across institutions, inadequate data sharing, workforce shortages, and lack of awareness, especially in resource-limited communities. This project aims to develop a hospital system-wide patient navigation protocol that can be scaled up to address OUD treatment linkage and continuity after hospitalization. |
||||||||
1R33DA059884-01
Show Summary |
ADAPT: Adaptive Decision Support for Addiction Treatment | Translation of Research to Practice for the Treatment of Opioid Addiction | Optimizing the Quality, Reach, and Impact of Addiction Services | NIDA | YALE UNIVERSITY | MELNICK, EDWARD ROBERT | New Haven, CT | 2023 |
NOFO Title: HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R33 Clinical Trial Optional)
NOFO Number: RFA-DA-23-054 Summary: Computerized clinical decision support tools offer a promising strategy to standardize and scale evidence-based practices to keep pace with the dynamic nature of the opioid crisis and overcome barriers to substance use disorder treatment. To change practice, such tools must be useful, usable, able to be integrated into routine care delivery, and supported by a multicomponent implementation strategy. This project will refine and evaluate the uptake, usability, and equity of a nationally disseminated multicomponent clinical decision support intervention to increase initiation of medication treatment for opioid use disorder in the emergency department. |
||||||||
1UG1DA059406-01
Show Summary |
Development and Validation of a Novel Point-of-Care Technology for Rapid Non-Targeted Identification of Emerging Opioid and Other Drug Threats | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Rapidly Assessing the Public Health Impact of Emerging Opioid Threats | NIDA | UNIVERSITY OF CALIFORNIA, SAN DIEGO | WERB, DANIEL M (contact); HALL, DREW ALEXANDER | La Jolla, CA | 2023 |
NOFO Title: HEAL Initiative: Rapidly Assessing the Public Health Impact of Emerging Opioid Threats (UG1 - Clinical Trial Not Allowed)
NOFO Number: RFA-DA-23-045 Summary: Drug checking services provide individuals who use drugs with information about the true contents of their purchases, and thus may help prevent overdoses. However, current technologies are either costly, technically complex, and non-portable or subject to false signals and restricted in their detection capabilities. This project will continue development of a new, simple-to-use, point-of-care analytical technology (DoseCheck) that can rapidly detect established drug threats in a sample and recognize newly emerging drugs. The project will also attempt to adapt DoseCheck to provide rapid results in emergency overdose situations and improve the analytical capabilities of medical examiners in under-resourced jurisdictions. |
||||||||
1RF1NS135504-01
Show Summary |
Development and Validation of a Porcine Model of Spinal Cord Injury-Induced Neuropathic Pain | Preclinical and Translational Research in Pain Management | Development and Optimization of Non-Addictive Therapies to Treat Pain | NINDS | EMORY UNIVERSITY | FLOYD, CANDACE L (contact); DATTA, SANDEEP R; GENSEL, JOHN C | Atlanta, GA | 2023 |
NOFO Title: HEAL Initiative: Development and Validation of Non-Rodent Mammalian Models of Pain (R01 Clinical Trial Not Allowed)
NOFO Number: RFA-NS-22-070 Summary: One of the most debilitating consequences of spinal cord injury is the development of chronic neuropathic pain, which is difficult to manage with existing pain treatments. Animal models and behavioral assays that better reflect the conditions in humans are urgently needed to help in identification of novel pain treatments. This project aims to develop a new model of spinal cord injury-related neuropathic pain using pigs, because they are similar to humans in anatomy, size, metabolism, physiology, and the way their bodies process drugs. |
||||||||
1R01DE033321-01
Show Summary |
Elucidating High Oral Fluid Exposure Mechanisms of Buprenorphine to Reduce Dental Caries | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Oral Complications Arising From Pharmacotherapies to Treat Opioid Use Disorders | NIDCR | UNIVERSITY OF HOUSTON | HU, MING (contact); WANG, BING-YAN | Houston, TX | 2023 |
NOFO Title: HEAL Initiative: Oral Complications Arising from Pharmacotherapies to Treat Opioid Use Disorders (R01 Clinical Trial Not Allowed)
NOFO Number: RFA-DE-23-015 Summary: Buprenorphine is commonly used in medication-assisted treatment of opioid use disorders. The U.S. Food and Drug Administration recently issued a warning that the drug may lead to serious tooth damage in some patients. It is thought that high concentrations of the drug in saliva may contribute to tooth damage and decay. This project will use a mouse model of dental caries to explore the mechanism leading to high buprenorphine concentrations in saliva and examine ways to reduce concentrations in the mouth but not the rest of the body; it will also examine buprenorphine’s effects on the bacteria that lead to caries development. |
||||||||
1SB1AR083748-01
Show Summary |
Commercial Readiness in CTS Pain Management | Cross-Cutting Research | Small Business Programs | NIAMS | HIGHLAND INSTRUMENTS, INC. | WAGNER, TIMOTHY ANDREW (contact); DIPIETRO, LAURA | Cambridge, MA | 2023 |
NOFO Title: HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management (SB1 Clinical Trial Not Allowed)
NOFO Number: PAR-23-069 |
||||||||
4R33NS114954-02
Show Summary |
The Inflammatory Index as a Biomarker for Pain in Patients with Sickle Cell Disease | Clinical Research in Pain Management | Discovery and Validation of Biomarkers, Endpoints, and Signatures for Pain Conditions | NINDS | MEDICAL COLLEGE OF WISCONSIN | BRANDOW, AMANDA M | Milwaukee, WI | 2023 |
NOFO Title: Discovery of Biomarkers, Biomarker Signatures, and Endpoints for Pain (R61/R33 Clinical Trial Optional)
NOFO Number: RFA-NS-18-041 |
||||||||
1R01DA059411-01
Show Summary |
Building Social and Structural Connections for the Prevention of OUD Among Youth Experiencing Homelessness: An RCT Examining Biopsychosocial Mechanisms | New Strategies to Prevent and Treat Opioid Addiction | Preventing Opioid Use Disorder | NIDA | OHIO STATE UNIVERSITY | FORD, JODI (contact); SLESNICK, NATASHA | Columbus, OH | 2023 |
NOFO Title: HEAL Initiative: Preventing Opioid Misuse and Co-Occurring Conditions by Intervening on Social Determinants (R01 - Clinical Trials Optional)
NOFO Number: RFA-DA-23-051 Summary: Multiple social determinants affect the health of youth experiencing homelessness. These include a lack of stable safe housing, income, education, food security, restricted access to services, as well as discrimination, victimization, and social isolation. This project will test the use of prevention efforts to address the factors that may be embedded within systems that serve this population, such as drop-in centers. The research will gather generalizable information about helping these youth along with cost estimates to inform future implementation efforts. |
||||||||
1RM1DA059377-01
Show Summary |
Person-Centered Quality Measurement and Management in a System for Addictions Treatment in New York State | Translation of Research to Practice for the Treatment of Opioid Addiction | Optimizing the Quality, Reach, and Impact of Addiction Services | NIDA | NEW YORK UNIVERSITY SCHOOL OF MEDICINE | NEIGHBORS, CHARLES J (contact); BURKE, CONSTANCE; LINCOURT, PATRICIA | New York, NY | 2023 |
NOFO Title: HEAL Initiative: Research to Foster an Opioid Use Disorder Treatment System Patients Can Count On (RM1 - Clinical Trial Optional)
NOFO Number: RFA-DA-23-046 Summary: The number of drug overdoses in New York continues to rise. In response, the New York State Office of Addiction Services and Supports (OASAS) is promoting approaches that embrace person-centered care, evidence-based practices, equitable treatment, and harm-reduction principles. In this project, researchers will partner with OASAS to build a quality measurement and management research center that provides performance feedback to support and encourage leadership and staff of treatment clinics to improve practice. The center will also publicize quality measures to ensure public accountability. |
||||||||
1R61DA059032-01A1
Show Summary |
Onsite PTSD Treatment to Improve MOUD Outcomes (OPTIMO): A Hybrid Type 1 Effectiveness-Implementation Trial of Harm Reduction PTSD Care at Syringe Service Programs | Translation of Research to Practice for the Treatment of Opioid Addiction | Optimizing the Quality, Reach, and Impact of Addiction Services | NIDA | CITY COLLEGE OF NEW YORK | LOPEZ-CASTRO, TERESA (contact); FOX, AARON D | New York, NY | 2023 |
NOFO Title: HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional)
NOFO Number: RFA-DA-23-053 Summary: People who inject drugs often have posttraumatic stress disorder (PTSD). Co-occurring PTSD puts these individuals at increased risk of illicit opioid use, opioid use disorder, overdose, HIV, and hepatitis C virus infection. This project will adapt, with input from the community, an evidence-based PTSD treatment program for people with both opioid use disorder and PTSD who are participating in a syringe service program. The treatment will then be tested in multiple syringe service programs to determine its potential for improving outcomes for these individuals who are often marginalized in traditional care. |
||||||||
1R01DA059423-01
Show Summary |
Automated Assessment of Maternal Sensitivity to Infant Distress: Leveraging Wearable Sensors for Substance Use Disorder Prevention and Research | Enhanced Outcomes for Infants and Children Exposed to Opioids | Virtual Assessments to Understand Developmental Trajectories of Substance Use Exposure | NIDA | UNIVERSITY OF TEXAS AT AUSTIN | DE BARBARO, KAYA | Austin, TX | 2023 |
NOFO Title: HEAL Initiative: Development and validation of virtual assessments to study children and caregivers in their natural environment (R01- Clinical Trial Not Allowed)
NOFO Number: RFA-DA-23-050 Summary: High-quality parent-infant interactions set the stage for secure parent-child attachment, self-reliance, and children’s ability to flexibly solve problems and “bounce back” from difficulties. This constellation of behaviors reduces the risk of developing substance use disorders later in life. This project will develop algorithms that use data from wearable sensors, trained separately for English- and Spanish-speaking families, to assess the quality of early mother-infant interactions objectively, automatically, and remotely in natural home environments, with the goal of developing tools to facilitate identification and prevention of early risks for substance use disorders. |
||||||||
1U24NS135547-01
Show Summary |
Meaningful Data Integration, Visualization and Distribution for Human Pain Associated Genes & Cells Datasets | Preclinical and Translational Research in Pain Management | Discovery and Validation of Novel Targets for Safe and Effective Treatment of Pain | NINDS | UNIVERSITY OF PENNSYLVANIA | WAGENAAR, JOOST B (contact); HUNTER, PETER JOHN; MARTONE, MARYANN E | Philadelphia, PA | 2023 |
NOFO Title: HEAL Initiative: Human Pain-associated Genes & Cells Data Coordination and Integration Center (U24 Clinical Trial Not Allowed)
NOFO Number: RFA-NS-22-021 Summary: The primary goal of the PRECISION Human Pain network and its participating centers is to generate comprehensive datasets of molecular signatures and cellular function phenotypes or signatures of various cell types that underlie transmission and processing of pain signals in humans. To maximize the impact of the data generated through this effort, it is vital to standardize and integrate all data generated by the various centers and make these data available in a meaningful way to the larger scientific community. As the Data Coordination and Integration Center, this project will support the network to curate, harmonize, and effectively integrate center-generated datasets as well as provide operational support for the network and conduct educational and outreach efforts. |
||||||||
1K99NS134965-01
Show Summary |
Lymphocyte Antigen 6 (Ly6) Proteins: New Players in Chronic Pain | Cross-Cutting Research | Training the Next Generation of Researchers in HEAL | NINDS | NEW YORK UNIVERSITY | GOMEZ, KIMBERLY | New York, NY | 2023 |
NOFO Title: HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)
NOFO Number: RFA-NS-22-025 Summary: Neuropathic pain—a debilitating form of chronic pain affecting millions of people—responds poorly to current analgesic treatment approaches. By better understanding the cellular mechanisms and compounds involved in neuropathic pain, researchers will be able to develop more targeted therapeutic approaches. This project will investigate the role that two proteins—Ly6e and Lynx1—play in various processes involved in the development of neuropathic pain, such as the activity of pain-triggering sensory neurons, interactions between neurons and immune cells, and the activity of an ion channel that has been implicated in the generation of pain signals. |
||||||||
1UG3NS135551-01
Show Summary |
Translating an MR-guided focused ultrasound system for first-in-human precision neuromodulation of pain circuits | Preclinical and Translational Research in Pain Management | Translating Discoveries into Effective Devices to Treat Pain | NINDS | VANDERBILT UNIVERSITY MEDICAL CENTER | CASKEY, CHARLES F (contact); CHEN, LI MIN | Nashville, TN | 2023 |
NOFO Title: Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)
NOFO Number: PAR-21-315 |
||||||||
2R44DE029369-02
Show Summary |
A Novel Opioid-Free Targeted Pain Control Method for Acute Post-Operative Localized Pain Related to Oral Surgical Procedures | Cross-Cutting Research | Small Business Programs | NINDS | REVBIO, INC. | JADIA, RAHUL (contact); KAY, GEORGE | Lowell, MA | 2023 |
NOFO Title: PHS 2022-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
NOFO Number: PA-22-176 |